PDS Biotechnology (FRA:EU6) Valuation Rank


FRA:EU6 PDS Biotechnology Corp FRA:EU6
32 GF Score
Price €0.75
! 1 Warning Sign
View Full Analysis

What is PDS Biotechnology Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

PDS Biotechnology Valuation Rank Related Terms

FRA:EU6
32GF Score
PDS Biotechnology Corp FRA:EU6
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PDS Biotechnology Business Description

Other Exchanges PDSB:USA
Address 303A College Road, East Princeton, NJ, USA, 08540
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
32GF Score

Get the complete analysis for FRA:EU6

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.75
Price